FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

asnington,	D.C. 20549		

OIVIB APPROVAL									
OMB Number:	3235-0287								
Estimated average	burden								

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

OIVID APPROVAL									
OMB Number:	3235-0287								
Estimated average burden									
hours per response:	0.5								

Name and Address of Reporting Person* LAROSA JOSEPH J				2. Issuer Name and Ticker or Trading Symbol REGENERON PHARMACEUTICALS, INC. [REGN]								Relationship of Reporting Perso (Check all applicable) Director Officer (give title				10% Owner Other (specify				
(Last)		(First) IILL RIVER I	(Middle)	` ′			3. Date of Earliest Transaction (Month/Day/Year) 02/07/2024								EVP General Counsel and Secret					
(Street)	ΓOWN	NY	10591		4. If /	4. If Amendment, Date of Original Filed (Month/Day/Year)							Individual or Joint/Group Filing (Check Applicabl Line) X Form filed by One Reporting Person Form filed by More than One Reporting Person					on		
(City)		(State)	(Zip)		Rul	Rule 10b5-1(c) Transaction Indication														
	Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan that is intende satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.									nded to										
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned																				
Date			2. Transac Date (Month/Da	Execution Date,		Transaction Disposed (Code (Instr. 5)		ies Acquired (A) or Of (D) (Instr. 3, 4 and		and	5. Amount of Securities Beneficially Owned Following		Forn (D) o	n: Direct or Indirect nstr. 4)	7. Nature of Indirect Beneficial Ownership					
								Code	v	Amount	(A) (D)	or Price	、 ·		ed ction(s) 3 and 4)			(Instr. 4)		
Common	Stock			02/07/	/2024				S		1,000		\$9	050 38		8,543		D		
Common Stock														3	,367			2022 GRAT		
Common Stock										35		355		I	By 401(k) Plan					
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																				
1. Title of Derivative Security (Instr. 3)	vative Conversion Date Execution Date, Truirity or Exercise (Month/Day/Year) if any C			Fransaction of Code (Instr. Derivative		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)		9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)					
					Code	v	(A)	(D)	Date Exercisa	able	Expiration Date	Title	Amount or Number of Shares							

Explanation of Responses:

/s/**Joseph LaRosa

** Signature of Reporting Person Date

02/09/2024

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

 $^{^{\}star}$ If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

^{**} Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).